A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Running, not enrolling · Phase 4

Conditions studied: Migraine

In brief

The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).

Key facts

Study ID
NCT06701526
Run by
H. Lundbeck A/S
People needed
164
Starts
2024-12-18
Expected to finish
2026-06-05
Last updated by the study team
2026-05-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.